Skip to main content
. 2020 Jun 15;9(13):e017559. doi: 10.1161/JAHA.120.017559

Figure 1. DOAC use in renal insufficiency.

Figure 1

*Apixaban dose adjustments are based on patient serum creatinine, age, and body weight; **rivaroxaban dose adjustments are based on patient indication; ***betrixaban: no dose adjustments provided for hemodialysis patients (has not been studied). CrCl indicates Cockcroft‐Gault creatinine clearance; ESRD, end‐stage renal disease; NVAF, nonvalvular atrial fibrillation; and VTE, venous thromboembolism.